ER+ HER2- Advanced Breast Cancer
ER+ HER2- advanced breast cancer is a type of breast cancer that is hormone receptor-positive and does not overexpress the HER2 protein, often requiring specific treatment approaches.
Advanced Solid Tumors: AZD8421 Study
We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
High-Grade Serous Ovarian Cancer (HGSOC)
High-grade serous ovarian cancer (HGSOC) is a common and aggressive form of ovarian cancer characterized by rapid growth and spread, often diagnosed at an advanced stage.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 18 years of age or older?
- Are you female?
- Do you have any unresolved health issues from previous cancer treatments, like severe side effects?
- Have you had any major surgery or significant injury in the last 4 weeks?
- Are you currently taking any medications that could interfere with the study, like strong painkillers or certain heart medications?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Camizestrant
Azd8421
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Algonad
Golexin
Golexin La
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hospital Universitari Vall D Hebron
Vall d' Hebron Institute of Oncology
Barcelona, Spain
Clinica Universidad De Navarra
Oncology Service
Ciudad Lineal, Spain
Clinica Universidad De Navarra
Oncology Service
Pamplona, Spain
Sponsor: Astrazeneca AB
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.